Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2002
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically focusing on SNP genotyping and gene expression profiling using proprietary BeadArray and Oligator technologies. The company has limited commercial product sales to date and relies heavily on research grants and strategic collaborations.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2002 |
6 Months Ended June 30, 2002 |
6 Months Ended July 1, 2001 |
|---|---|---|---|
| Total Revenue | $1,900 | $3,169 | $1,034 |
| Net Loss | $(16,447) | $(25,114) | $(10,811) |
| Net Loss Per Share (Basic/Diluted) | $(0.54) | $(0.82) | $(0.37) |
| Cash and Cash Equivalents | $705 | $705 (End of Period) | $11,423 (End of Period) |
| Total Investments (Available for Sale) | $79,378 | $79,378 (End of Period) | $89,621 (End of Period) |
| Total Debt (Current + Long-Term) | $26,175 | $26,175 (End of Period) | $0 (End of Period) |
| Accumulated Deficit | $(75,200) as of June 30, 2002 |
Liquidity: As of June 30, 2002, the company held approximately $80.1 million in cash, cash equivalents, and investments. Management expects these resources to fund operations for at least the next 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the six months ended June 30, 2002, increased to $3.2 million from $1.0 million in the prior year period. This growth was driven primarily by increased sales of custom oligonucleotides and SNP genotyping services.
- Increased Operating Loss: Net loss for the six-month period widened significantly to $25.1 million from $10.8 million in the prior year. This was driven by a $7.7 million litigation judgment charge and increased operating expenses.
- Debt Assumption: In January 2002, the company assumed a $26 million, 10-year mortgage to purchase its new facility, resulting in a significant increase in interest expense compared to the prior year.
- Operating Expenses: Research and Development (R&D) expenses increased by $4.6 million year-over-year for the six-month period due to higher headcount and supply costs for BeadArray technology development. General and Administrative (G&A) expenses increased by $1.4 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Product Launch: Due to delays in a collaboration with Applied Biosystems, Illumina decided to launch its own high-throughput SNP genotyping system, expected to be available for shipment in the fourth quarter of 2002.
- Profitability: The company expects to continue incurring substantial and increasing costs for R&D and manufacturing scale-up. Significant revenue growth is required to achieve profitability.
- Capital Needs: While current funds are expected to last 24 months, the company may require additional funding sooner if commercialization efforts accelerate or if market conditions change.
Risks and Contingencies
- Litigation: A $7.7 million charge was recorded for a termination-of-employment lawsuit. The company plans to appeal the verdict, believing the termination was lawful.
- Collaboration Uncertainty: The launch of the joint SNP genotyping system with Applied Biosystems has been delayed indefinitely, creating uncertainty regarding future revenue from that partnership.
- Market Acceptance: As an early-stage company with no commercially available microarray or scanning instrument products, success depends on market adoption of unproven technology.
- Manufacturing: The company has limited experience in commercial-scale manufacturing and relies on a single facility and limited suppliers for key components.
Investor Verification Checklist
- Litigation Status: Verify the progress of the appeal regarding the $7.7 million employment lawsuit and potential cash outflows.
- Product Timeline: Confirm the readiness and shipment schedule of the proprietary SNP genotyping system planned for Q4 2002.
- Collaboration Terms: Monitor communications with Applied Biosystems regarding the delayed joint product launch and potential impact on deferred revenue recognition.
- Cash Burn Rate: Assess whether the current $80 million liquidity position is sufficient given the increased R&D spend and new debt service obligations.
- Revenue Mix: Track the transition from grant-dependent revenue to product and service revenue to evaluate long-term sustainability.